OBJECTIVELow vitamin D status has been associated with impaired glycemic control in patients with type 2 diabetes. The purpose of our study was to evaluate the effect of vitamin D supplementation on glycemic control in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODSThis randomized, double-blind, placebo-controlled trial was conducted in 275 adult patients with type 2 diabetes without insulin treatment. Patients were randomly assigned to receive either vitamin D 3 (50,000 IU/month) or placebo for 6 months. To assess the primary outcome of the study, change in HbA 1c , we performed a linear regression analysis.
RESULTS
Mean baseline serum 25-hydroxyvitamin D [25(OH)D]increased from 60.6 6 23.3 to 101.4 6 27.6 nmol/L and 59.1 6 23.2 to 59.8 6 23.2 nmol/L in the vitamin D and placebo group, respectively. Mean baseline HbA 1c was 6.8 6 0.5% (51 6 6 mmol/mol) in both groups. After 6 months, no effect was seen on HbA 1c (mean difference: b = 0.4 [95% CI 20.6 to 1.5]; P = 0.42) and other indicators of glycemic control (HOMA of insulin resistance, fasting insulin, and glucose) in the entire study population. Subgroup analysis in patients with a serum 25(OH)D <50 nmol/L or an HbA 1c level >7% (53 mmol/mol) did not differ the results.
CONCLUSIONSIn a well-controlled group of patients with type 2 diabetes, intermittent high-dose vitamin D supplementation did not improve glycemic control.Type 2 diabetes, characterized by peripheral insulin resistance and pancreatic b-cell dysfunction, represents a worldwide epidemic with significant comorbidity and mortality due to microvascular and macrovascular complications (1). Although therapies for type 2 diabetes have improved over the last few decades, new insights for the prevention and management of type 2 diabetes remain necessary due to the increased prevalence of the disease.